该公司开发了具有自主知识产权的ADC相关技术,其适应症涵盖了发病率和死亡率最高的10个肿瘤领域。
下表是宜联项目管线的最新进展:
Project
Target
Indications
Platform
Collaboration
Discovery
Pre -Clinical
IND
Phase 1
Phase 2
Phase 3
BLA
B7H3
Solid Tumor
YL202
HER3
Solid Tumor
BioNTech
YL203
Undisclosed
Solid Tumor
Evopoint
YL204
Undisclosed
Solid Tumor
Evopoint
YL205
Undisclosed
Solid Tumor
YL211
C-MET
Solid Tumor
Roche
YL212
DLL3
Solid Tumor
Zai Lab
YL215
MSLN
Solid Tumor
Harbour
YL221
EGFR
Solid Tumor
Henlius
YL222
PDL1
Solid Tumor
Henlius
YL216 | YL217
YL218
Undisclosed
Solid Tumor
YL231 | LYL232
YL233 | YL234
Undisclosed
Solid Tumor